LONDON – It's the technology that keeps on giving, and the Heptares unit of Sosei Group Corp. has attracted a further partner to its G protein-coupled receptor (GPCR) platform, signing up Takeda Pharmaceutical Ltd., in a deal worth up to $1.2 billion. Read More
Shares of California-based Allakos Inc. (NASDAQ:ALLK) rose 110.5% to a record close of $65.26 Monday amid a broader market plunge on positive phase II results with AK-002, its experimental therapy for people with two rare conditions, eosinophilic gastritis (EG) and eosinophilic gastroenteritis (EGE). Read More
Deciphera Pharmaceuticals Inc. CEO Steven Hoerter told BioWorld the FDA approval of Turalio (pexidartinib) from Daiichi Sankyo Co. Ltd. last week "leaves a lot of headroom for efficacy," given the response rate of about 40%. Read More
No day is a good one for a company connected to a failed phase III trial, but Monday's hammering of Glycomimetics Inc. (NASDAQ:GLYC) shares was particularly tough as the greater market's weakness provided no shelter. Read More
It appeared that investors were far more interested in their vacations than in tracking the progress of blue-chip biopharma companies last month. Read More
HONG KONG – Vietnam is emerging as a favorable market for multinational drugmakers, thanks to new trade agreements that provide more protection to patent holders and policies that welcome drug imports. Some companies have already made their moves in the populated Southeast Asian country. Read More
We're working to enhance BioWorld's news services by moving to a brand-new platform later this year. Upgrades will include: same-day news delivery, improved functionality, easier accessibility on all devices, more analysis and dynamic data visualization. We value your opinion on these changes. Please take 2 minutes to complete this short survey to help guide our work: https://www.surveymonkey.com/r/Q5TK8JL Read More
Rafael Pharmaceuticals Inc., of Newark, N.J., launched Rafael Trial Connect, a website intended to help cancer patients access information about its clinical trials and provide up-to-date trial information about the studies to oncologists. Read More
3-V Biosciences Inc., of San Mateo, Calif., changed its name to Sagimet Biosciences Inc. and closed a second tranche of its series E financing, which now totals $25 million. Read More
Going into Wednesday's Antimicrobial Drug Advisory Committee meeting, FDA reviewers appear comfortable with the clinical data to support approval of a second Gilead Sciences Inc. drug, Descovy (emtricitabine/tenofovir alafenamide), as a pre-exposure prophylaxis (PrEP) for HIV infections in men and transgender women who have sex with men (MSM/TGW). Read More
